A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
← catalyst calendarNCT06627647 · readout in 1,552 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,160estimated
Sites
295
Countries
Argentina, Australia, Belgium +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-27 | actual | When the study began enrolling |
| Primary completion | 2030-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-squamous Non-small Cell Lung Cancer
Interventions
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Pembrolizumab — also filed as Keytruda
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFOverall survival (OS)
measured Up to approximately 6 years
Progression-free survival (PFS)
measured Up to approximately 6 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed